期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 10, 期 7, 页码 885-895出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.917962
关键词
biological therapy; CAM; Crohn's disease; inflammatory bowel disease; integrins; monoclonal antibody; pathogenesis; ulcerative colitis
类别
资金
- Schering-Plough
- Astra Zeneca
- Abbott Laboratories
- Novo Nordisk
- Takeda Millennium
- Danone
- Salix Pharmaceuticals
- Pfizer
- UCB Pharma
- UCB Pharma, Ferring
- Vifor
- Merck Sharp Dohme
- AbbVie
- MSD
- Takeda
- Janssen
- UCB
- Merck Co, Inc.
Inflammatory bowel diseases (IBD) are chronic, relapsing to continuously active inflammatory disorders of the gastrointestinal tract, of potentially destructive nature. So far, the excessive and/or unbalanced immune response has been the target of the majority of the IBD treatments. Despite the increasing use of immunosuppressants and anti-TNF- inhibitors, about 30% of patients with Crohn's disease and about one-tenth of patients with ulcerative colitis still require major abdominal surgery at 5-10 years. As a result, new therapeutic approaches are urgently needed. The endothelium has a key role in the development of the inflammation, as it selectively governs the leukocyte trafficking and the influx of leukocytes into the intestinal mucosa. Drugs blocking such crossing, specifically at intestinal level, are going to be a new therapeutic option in IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据